Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sildenafil in univentricular heart disease with pulmonary hypertension
2018-004828-11Phase 3Active
- Sponsor
- Centre Hospitalier Universitaire de Montpellier
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Single Ventricle Heart Defects and pulmonary arterial hypertension (PAH) comparing Sildenafil (Mysildecard) with Placebo (2 arms). Primary endpoint: Change in VE/VCO2 slope. Started Mar 2019; status: active.
02
Drugs
sildenafil
03
Conditions
Single Ventricle Heart Defectspulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2018-004828-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004828-11.